CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Pemetrexed +3 moredrug
Likely dose
Bevacizumab 7.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01063283
NCT01063283N/ACompleted
CompareCT.gov

A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer

University of Chicago·interventional·Posted Feb 5, 2010·Updated Nov 18, 2019

In Brief

A clinical study evaluating Pemetrexed, Carboplatin, and 2 other interventions for Advanced Non-squamous Non-Small Cell Lung Cancer. Completed, enrolled 20 participants across 3 sites.

Detailed Summary

The purpose of this study is to see if higher dose of bevacizumab can be taken safely by some patients and if changes in the dose of bevacizumab have any effect on blood pressure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-squamous Non-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 5, 2010
Enrollment StartMar 1, 2010
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 16.4 years ago

Interventions

Pemetrexeddrug

Pemetrexed 500 mg/m\^2 intravenously over 10 minutes

Carboplatindrug

Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes

Bevacizumab 7.5 mg/kgdrug

Bevacizumab at 7.5 mg/kg intravenously over 90 minutes

Bevacizumab 15 mg/kgdrug

Bevacizumab at 15 mg/kg intravenously over 90 minutes